PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study will examine extreme responders to second- and third-line Type 2 diabetes therapy
using a prospective approach, and patients with slow or fast diabetes progression using a
retrospective approach.
Details
Lead Sponsor:
NIHR Exeter Clinical Research Facility Royal Devon and Exeter NHS Foundation Trust
Collaborators:
King's College Hospital NHS Trust King's College London Newcastle University Newcastle-upon-Tyne Hospitals NHS Trust NHS Greater Glasgow and Clyde Oxford University Hospitals NHS Trust Royal Devon and Exeter NHS Foundation Trust University of Exeter University of Glasgow
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sodium-Glucose Transporter 2 Inhibitors